Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR13780267

· cohortMD1

8a53bb38-af0e-5064-9a6a-2bdfe13d1824

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortMD1
subtype
cohortMD1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.430
  • G2M_CHECKPOINT+0.390
  • MITOTIC_SPINDLE+0.350
  • MYC_TARGETS_V1+0.340
  • MYC_TARGETS_V2+0.260
  • DNA_REPAIR+0.230
  • GLYCOLYSIS+0.210
  • UNFOLDED_PROTEIN_RESPONSE+0.150
  • UV_RESPONSE_DN+0.080
  • BILE_ACID_METABOLISM+0.040

Top 10 suppressed

  • IL6_JAK_STAT3_SIGNALING-0.470
  • INFLAMMATORY_RESPONSE-0.470
  • ANGIOGENESIS-0.440
  • ALLOGRAFT_REJECTION-0.430
  • INTERFERON_GAMMA_RESPONSE-0.430
  • INTERFERON_ALPHA_RESPONSE-0.420
  • TNFA_SIGNALING_VIA_NFKB-0.390
  • COMPLEMENT-0.340
  • APOPTOSIS-0.330
  • PANCREAS_BETA_CELLS-0.330

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-66-2793-01A-01R-1201-07
lung-landscapes@6
cohortMD10.920
2TCGA-33-4587-01A-11R-2125-07
lung-landscapes@6
cohortMD10.915
3C3L-04013
lung-landscapes@6
cohortMD10.908
4SJEPD030795_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.908
5TCGA-O2-A5IB-01A-11R-A27Q-07
lung-landscapes@6
cohortMD10.904
6TCGA-43-6143-01A-11R-1820-07
lung-landscapes@6
cohortMD10.901
7BS_53M8PP88
medullo-epn-umap@date-based
EPNEPN Tumor0.898
8MNG903
mng-umap@100
0.894
9SRR13780247
lung-landscapes@6
cohortMD10.894
10MDT-AP-1234
medullo-epn-umap@date-based
MedMedulloblastoma0.890

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 13 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.430Inavolisib— uncovered
G2M_CHECKPOINT0.390Inavolisib— uncovered
MITOTIC_SPINDLE0.350Inavolisib— uncovered
MYC_TARGETS_V10.340Inavolisib— uncovered
MYC_TARGETS_V20.260Idelalisib— uncovered
DNA_REPAIR0.230Idelalisib— uncovered
GLYCOLYSIS0.210Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.150Idelalisib— uncovered
UV_RESPONSE_DN0.080Inavolisib— uncovered
BILE_ACID_METABOLISM0.040Inavolisib— uncovered
PEROXISOME0.040Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.030Inavolisib— uncovered
FATTY_ACID_METABOLISM0.020Inavolisib— uncovered